Patents by Inventor Dajian Yang

Dajian Yang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10973823
    Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 13, 2021
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Guoqing Chen, Ruihong Gong, Dajian Yang, Aiping Lyu
  • Publication number: 20190388424
    Abstract: Provided is a combined pharmaceutical composition of HF and an Artemisia annua sesquiterpene lactone compound for treating cancers. The active ingredients of the combined pharmaceutical composition consist of HF and an Artemisia annua sesquiterpene lactone compound. HF and ATS have significant synergistic effect. The activity of the combined pharmaceutical of HF and ATS is comparable or even higher than that of the anti-cancer drug 5-FU.
    Type: Application
    Filed: September 27, 2016
    Publication date: December 26, 2019
    Inventors: Zhaoxiang BIAN, Guoqing CHEN, Ruihong GONG, Dajian YANG, Aiping LYU
  • Patent number: 9868716
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 16, 2018
    Assignees: HONG KONG BAPTIST UNIVERSITY, SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE
    Inventors: Hongxi Xu, Yue Lv, Wenwei Fu, Kaixian Chen, Zhaoxiang Bian, Shilin Chen, Dajian Yang, Aiping Lu, Sun Chi Albert Chan
  • Patent number: 9775857
    Abstract: The present invention relates to chemical constituents of the hydro-alcoholic extract of root of Lasia spinosa (L.) Thwait. More particularly, it relates to the bioactive chemical composition of Lasia spinosa (L.) Thwait and its anticancer effect. The present invention has application in the treatment of human esophageal carcinoma.
    Type: Grant
    Filed: June 23, 2016
    Date of Patent: October 3, 2017
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20170035824
    Abstract: Disclosed is a natural compound, Oblongifolin C, isolated from a natural plant comprising Garcinia species such as Garcinia yunnanesis Hu, for its effects of anti-migration and anti-invasion against cancer and its use as an anticancer drug. The treated cancers comprise cervical cancers and esophageal cancers. The cancer treatment comprises inhibition of cancer metastasis and inhibition of autophagic flux.
    Type: Application
    Filed: October 19, 2016
    Publication date: February 9, 2017
    Inventors: Hongxi XU, Yuanzhi LAO, Hongsheng TAN, Naihan XU, Xiaoyu WANG, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20160374985
    Abstract: The present invention disclosed a compound, proanthocyanidin A1 (PA1), which is isolated from Lasia spinosa (L.) Thwait, for its effects in shortening of clolon length, reducing colonic tissue damage, suppressing colonic myeloperoxidase activity with colitis. The said compound can be used in treating inflammatory diseases and anti-cancer leading compound.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Publication number: 20160375082
    Abstract: The present invention relates to chemical constituents of the hydro-alcoholic extract of root of Lasia spinosa (L.) Thwait. More particularly, it relates to the bioactive chemical composition of Lasia spinosa (L.) Thwait and its anticancer effect. The present invention has application in the treatment of human esophageal carcinoma.
    Type: Application
    Filed: June 23, 2016
    Publication date: December 29, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Hongxi Xu, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Patent number: 9408811
    Abstract: Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound of formula (I): More particularly, it relates to said anti-prostate cancer compound that can be isolated from Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: August 9, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Hongxi Xu, Xin Li, Hong Zhang, Yuanzhi Lao, Hongsheng Tan, Xiaoyu Wang, Kaixian Chen, Zhaoxiang Bian, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan
  • Patent number: 9408828
    Abstract: The present invention provides a compound, namely (+)-3?-Angeloyloxy-4?-keto-3?,4?-dihydroseselin (Pd-Ib) derived from Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
    Type: Grant
    Filed: June 18, 2015
    Date of Patent: August 9, 2016
    Inventors: Zhaoxiang Bian, Huaixue Mu, Chengyuan Lin, Quanbin Han, Aiping Lu, Linfang Huang, Shilin Chen, Dajian Yang, Hongxi Xu, Sun Chi Albert Chan
  • Publication number: 20160185744
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt, hydrate or prodrug thereof for inhibiting Syk activity,
    Type: Application
    Filed: August 12, 2015
    Publication date: June 30, 2016
    Inventors: Hongxi XU, Yue LV, Wenwei FU, Kaixian CHEN, Zhaoxiang BIAN, Shilin CHEN, Dajian YANG, Aiping LU, Sun Chi Albert CHAN
  • Patent number: 9339488
    Abstract: Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: May 17, 2016
    Assignee: HONG KONG BAPTIST UNIVERSITY
    Inventors: Hongxi Xu, Hong Zhang, Yuanzhi Lao, Xiaoyu Wang, Kaixian Chen, Dajian Yang, Shilin Chen, Chengyuan Lin, Zhaoxiang Bian, Aiping Lu, Albert Sun Chi Chan
  • Patent number: 9260466
    Abstract: A method for suppressing activation of pancreatic stellate cells of a subject includes administering a composition comprising a therapeutically effective amount of Eruberin A. A method of preventing, alleviating or treating pancreatic tumors or pancreatic tumors related diseases includes administering a composition comprising a therapeutically effective amount of Eruberin A. The Eruberin A may be extracted from Pronephrium penangianum.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: February 16, 2016
    Assignee: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Siu Wai Tsang, Hongjie Zhang, Yegao Chen, Aiping Lu, Albert Sun-Chi Chan, Hongxi Xu, Shilin Chen, Dajian Yang
  • Publication number: 20150366841
    Abstract: The present invention provides a compound, namely (+)-3?-Angeloyloxy-4?-keto-3?, 4?-dihydroseselin (Pd-Ib) derived from Bupleurum malconense as the potential anti-inflammation drug. The present invention also relates to methods of preparing the compounds and using the same for treating inflammation.
    Type: Application
    Filed: June 18, 2015
    Publication date: December 24, 2015
    Inventors: Zhaoxiang BIAN, Huaixue MU, Chengyuan LIN, Quanbin HAN, Aiping LU, Linfang HUANG, Shilin CHEN, Dajian YANG, Hongxi XU, Sun Chi Albert CHAN
  • Publication number: 20150231090
    Abstract: The present invention provides composition for treating cancer comprising polyprenylated acylphloroglucinol (PPAP) compound. The present invention also provides a composition comprising Guttiferone K for treating esophageal cancer and liver cancer. The present invention further provides a method of using said compound for inhibiting cancer metastasis.
    Type: Application
    Filed: May 1, 2015
    Publication date: August 20, 2015
    Inventors: Hongxi XU, Kaikai SHEN, Yuanzhi LAO, Hongsheng TAN, Kaixian CHEN, Dajian YANG, Shilin CHEN, Zhaoxiang BIAN, Chengyuan LIN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150038569
    Abstract: Cervical cancer is one of the most common malignancies and is associated with a dismal prognosis. The most common therapeutic option for cervical cancer consists of surgery in early stages, and chemotherapy or radiotherapy in more advanced stages of the disease. Although treatment options have increased for some patients, overall progress has been modest. This invention relates to a method for treating cancer comprising administering an anti-cancer compound. More particularly, the present invention relates to an anti-cervical-cancer compound for treating human cervical cancer and tumor.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 5, 2015
    Inventors: Hongxi XU, Hong ZHANG, Yuanzhi LAO, Xiaoyu WANG, Kaixian CHEN, Dajian YANG, Shilin CHEN, Chengyuan LIN, Zhaoxiang BIAN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150025155
    Abstract: Prostate cancer is the most commonly diagnosed cancer in males and one of the leading causes of cancer death. Although treatment options have increased for some patients, overall progress has been modest. Thus, there is a great need to develop new treatments. This invention relates to a method for treating cancer comprising using an anti-cancer compound. More particularly, it relates to an anti-prostate cancer compound that can be isolated from Garcinia esculenta or chemically synthesized and its specific anticancer/antitumor activity. The invention has a specific application in treating human prostate cancer.
    Type: Application
    Filed: July 17, 2014
    Publication date: January 22, 2015
    Inventors: Hongxi XU, Xin LI, Hong ZHANG, Yuanzhi LAO, Hongsheng TAN, Xiaoyu WANG, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20150011646
    Abstract: This invention is related to compounds isolated from various Garcinia species and method of treating cancer. The present invention provides composition for treating cancer comprising polyprenylated acylphloroglucinol (PPAP) compound. The present invention also provides a composition comprising Guttiferone K for treating esophageal cancer.
    Type: Application
    Filed: January 8, 2014
    Publication date: January 8, 2015
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Yuanzhi LAO, Zhichao XI, Hongsheng TAN, Kaixian CHEN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Aiping LU, Albert Sun Chi CHAN
  • Publication number: 20140348965
    Abstract: A method for suppressing activation of pancreatic stellate cells of a subject includes administering a composition comprising a therapeutically effective amount of Eruberin A. A method of preventing, alleviating or treating pancreatic tumors or pancreatic tumors related diseases includes administering a composition comprising a therapeutically effective amount of Eruberin A. The Eruberin A may be extracted from Pronephrium penangianum.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 27, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Zhaoxiang Bian, Siu Wai Tsang, Hongjie Zhang, Yegao Chen, Aiping Lu, Albert Sun-Chi Chan, Hongxi Xu, Shilin Chen, Dajian Yang
  • Publication number: 20140235877
    Abstract: The present invention provides two compounds, namely Compound A and B, as the potential anticancer drug, and a composition comprising said Compound A and/or B for treating cancer or tumor related diseases. The present invention also relates to methods of preparing the compounds from a natural source and a composition comprising the compounds, and using the same for treating cancer or tumor related diseases.
    Type: Application
    Filed: March 31, 2014
    Publication date: August 21, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi XU, Zhengxiang XIA, Yuanzhi LAO, Hongsheng TAN, Zhaoxiang BIAN, Dajian YANG, Shilin CHEN, Kaixian CHEN, Albert Sun-Chi CHAN
  • Publication number: 20140200265
    Abstract: This invention relates to the use of a natural compound from natural sources for its therapeutic uses. More particularly, it relates to a compound 1,3,5,7-tetrahydroxy-8-isoprenylxanthone (TI, FIG. 1), that is naturally occurring in the plant of Garcinia esculenta Y. H. Li, and its biological activity of inhibiting nitric oxide production and microRNA 155 expression in stimulated macrophages, which can be developed as potential anti-inflammatory drugs.
    Type: Application
    Filed: January 8, 2014
    Publication date: July 17, 2014
    Applicant: Hong Kong Baptist University
    Inventors: Hongxi Xu, Dandan Zhang, Hong Zhang, Kaixian Chen, Zhaoxiang Bian, Chengyuan Lin, Dajian Yang, Shilin Chen, Aiping Lu, Albert Sun Chi Chan